Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sucampo Submits NDA For Constipation Agent Lubiprostone

This article was originally published in The Pink Sheet Daily

Executive Summary

Standard review is expected, setting a user fee deadline in January 2006. Sucampo plans to begin Phase III trials in constipation-predominant irritable bowel syndrome “soon.” The oral agent would be marketed by Takeda’s U.S. subsidiary.

You may also be interested in...



Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter

Co-promotion partner Takeda will focus sales activities on office-based gastroenterologists and primary care physicians, while Sucampo will target medical centers and the VA.

Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter

Co-promotion partner Takeda will focus sales activities on office-based gastroenterologists and primary care physicians, while Sucampo will target medical centers and the VA.

Novartis' Zelnorm Approved For Chronic Constipation Without Gender Restrictions

FDA approves the supplemental indication despite an advisory committee recommendation that tegaserod use be limited to women. The agency follows the committee's recommendation on use only in individuals under age 65.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel